ANAGRELIDE/ ANAGRELIDE B&B/ ANAGRELIDE MEDSURGE/ ANAGRIDE/ ANAGREDEX/ ANAGRELIDE MEDICIANZ (Micro Labs Pty Ltd)

Product name

ANAGRELIDE/ ANAGRELIDE B&B/ ANAGRELIDE MEDSURGE/ ANAGRIDE/ ANAGREDEX/ ANAGRELIDE MEDICIANZ

Date registered

6 December 2023

Evaluation commenced

3 January 2023

Decision date

27 November 2023

Approval time

153 (255 working days)

Active ingredients

anagrelide hydrochloride

Registration type

New generic medicine

Indication

ANAGRIDE capsules are indicated for the treatment of essential thrombocythaemia.

Registration process

First generic

First approval of a medicine that contains the same active ingredient as and is bioequivalent to an existing medicine